MX383771B - Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos. - Google Patents

Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos.

Info

Publication number
MX383771B
MX383771B MX2015016549A MX2015016549A MX383771B MX 383771 B MX383771 B MX 383771B MX 2015016549 A MX2015016549 A MX 2015016549A MX 2015016549 A MX2015016549 A MX 2015016549A MX 383771 B MX383771 B MX 383771B
Authority
MX
Mexico
Prior art keywords
oxymetazoline
cough
treatment
ipratropium
combination
Prior art date
Application number
MX2015016549A
Other languages
English (en)
Other versions
MX2015016549A (es
Inventor
Borrego Pablo Cortés
Original Assignee
Pablo Cortes Borrego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58797489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383771(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pablo Cortes Borrego filed Critical Pablo Cortes Borrego
Priority to MX2015016549A priority Critical patent/MX383771B/es
Priority to US15/778,067 priority patent/US10391087B2/en
Priority to CN201680070651.5A priority patent/CN108472287A/zh
Priority to BR112018011012A priority patent/BR112018011012A2/pt
Priority to EP16871105.9A priority patent/EP3384909B1/en
Priority to PCT/MX2016/000028 priority patent/WO2017095210A1/es
Priority to JP2018529088A priority patent/JP2018536008A/ja
Priority to CA3007697A priority patent/CA3007697C/en
Priority to ES16871105T priority patent/ES3010113T3/es
Publication of MX2015016549A publication Critical patent/MX2015016549A/es
Priority to CONC2018/0005687A priority patent/CO2018005687A2/es
Publication of MX383771B publication Critical patent/MX383771B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención es efectiva para el tratamiento y el alivio de la tos producida por secreción nasal posterior, mediante el uso de la combinación de Oximetazolina e Ipratropio. Los agentes activos enunciados en la combinación de la presente invención, se han utilizado y comercializado por separado con usos diferentes a los de la presente invención. La oximetazolina para eliminar la secreción y la congestión (obstrucción) nasal, y el bromuro de ipratropio se comercializa para efectos de dilatar los bronquios en los pacientes asmáticos y con enfermedad pulmonar obstructiva crónica, aunque experimentalmente se ha utilizado también para disminuir la secreción nasal. Ambos agentes activos, juntos o por separado no se han utilizado hasta ahora como antitusígenos por vía intranasal. La tos producida por la secreción nasal posterior, es la causa más frecuente de tos en el ser humano de cualquier edad, la presente invención es efectiva para el tratamiento y el alivio de dicho síntoma.
MX2015016549A 2015-12-02 2015-12-02 Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos. MX383771B (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2015016549A MX383771B (es) 2015-12-02 2015-12-02 Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos.
ES16871105T ES3010113T3 (en) 2015-12-02 2016-03-17 Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough
EP16871105.9A EP3384909B1 (en) 2015-12-02 2016-03-17 Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough
CN201680070651.5A CN108472287A (zh) 2015-12-02 2016-03-17 用于治疗咳嗽的局部鼻部应用的羟基甲唑啉和异丙托铵的组合
BR112018011012A BR112018011012A2 (pt) 2015-12-02 2016-03-17 combinação de oximetazolina e ipratrópio em aplicação nasal tópica para o tratamento da tosse
US15/778,067 US10391087B2 (en) 2015-12-02 2016-03-17 Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough
PCT/MX2016/000028 WO2017095210A1 (es) 2015-12-02 2016-03-17 Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos
JP2018529088A JP2018536008A (ja) 2015-12-02 2016-03-17 咳の治療のための局所的鼻適用におけるオキシメタゾリンとイプラトロピウムの組み合わせ
CA3007697A CA3007697C (en) 2015-12-02 2016-03-17 Combination of oxymetazoline and ipratropium for topical nasal application for the treatment of cough
CONC2018/0005687A CO2018005687A2 (es) 2015-12-02 2018-05-30 Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015016549A MX383771B (es) 2015-12-02 2015-12-02 Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos.

Publications (2)

Publication Number Publication Date
MX2015016549A MX2015016549A (es) 2017-06-01
MX383771B true MX383771B (es) 2025-03-14

Family

ID=58797489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016549A MX383771B (es) 2015-12-02 2015-12-02 Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos.

Country Status (10)

Country Link
US (1) US10391087B2 (es)
EP (1) EP3384909B1 (es)
JP (1) JP2018536008A (es)
CN (1) CN108472287A (es)
BR (1) BR112018011012A2 (es)
CA (1) CA3007697C (es)
CO (1) CO2018005687A2 (es)
ES (1) ES3010113T3 (es)
MX (1) MX383771B (es)
WO (1) WO2017095210A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1290502C (zh) * 2001-09-18 2006-12-20 丹麦奈科明有限公司 治疗普通感冒的组合物
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
CA2641605A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
WO2014158119A1 (en) * 2013-03-29 2014-10-02 Santa Farma İlaç Sanayi̇ A.Ş Aqueous solution composition containing ipratropium and oxymetazoline

Also Published As

Publication number Publication date
US10391087B2 (en) 2019-08-27
CO2018005687A2 (es) 2018-07-19
WO2017095210A1 (es) 2017-06-08
CN108472287A (zh) 2018-08-31
EP3384909C0 (en) 2024-12-25
BR112018011012A2 (pt) 2018-11-21
EP3384909A4 (en) 2019-07-24
EP3384909A1 (en) 2018-10-10
US20180344722A1 (en) 2018-12-06
EP3384909B1 (en) 2024-12-25
ES3010113T3 (en) 2025-04-01
CA3007697A1 (en) 2017-06-08
MX2015016549A (es) 2017-06-01
CA3007697C (en) 2025-05-06
JP2018536008A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
CO2019005236A2 (es) Métodos para tratar afecciones inflamatorias
CL2018002137A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400)
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
BR112016009995A2 (pt) compostos agonistas triplos glucagon-glp-1-gip
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
IL283929A (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
BR112015029970A2 (pt) inibidores de cinase
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX389962B (es) Metodos para tratar trastornos mitocondriales y metabolicos.
LT3890767T (lt) Inhaliuojamos kompozicijos, skirtos naudoti plaučių ligų gydymui
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX392677B (es) Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
MX395722B (es) Terapia de combinación para enfermedad pulmonar obstructiva crónica (epoc).
IL286268A (en) Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
IL264372A (en) Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CL2017000478A1 (es) Compuesto de pirazolotiazol y medicamento que comprende el mismo.
EA201792056A1 (ru) Лечение пациентов с сахарным диабетом 2 типа